Skip to contentP
Processa Pharmaceuticals, Inc.
P
PCSAProcessa Pharmaceuticals, Inc. Q1 2018 · 10-Q
Revenue—
Net Income-$1.10M-$1.10MN/M vs Q1 2017 EPS Diluted-$0.03-$0.03N/M vs Q1 2017 Operating Income-$1,291,616N/M Operating Cash Flow-$1,069,008N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR
ended Mar 31, 2018 · filed May 21, 2018 · 51 d after period end